News
![DGAP-Adhoc: Heidelberg Pharma AG plant Kapitalmaßnahme zur Finanzierung des ATAC-Entwicklungsprogramms](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-Adhoc: Heidelberg Pharma AG plant Kapitalmaßnahme zur Finanzierung des ATAC-Entwicklungsprogramms
DGAP-Adhoc: Heidelberg Pharma AG plant Kapitalmaßnahme zur Finanzierung des ATAC-Entwicklungsprogramms
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![DGAP-Adhoc: CO.DON AG: Verzögerung Veröffentlichung Jahresabschluss, Vereinbarung über Zuführung weiterer Liquidität, beabsichtigte Kapitalerhöhung](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
DGAP-Adhoc: CO.DON AG: Verzögerung Veröffentlichung Jahresabschluss, Vereinbarung über Zuführung weiterer Liquidität, beabsichtigte Kapitalerhöhung
DGAP-Adhoc: CO.DON AG: Verzögerung Veröffentlichung Jahresabschluss, Vereinbarung über Zuführung weiterer Liquidität, beabsichtigte Kapitalerhöhung
![DGAP-Adhoc: CO.DON AG: Delayed publication of financial statements, agreement on provision of additional liquidity, planned capital increase](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
DGAP-Adhoc: CO.DON AG: Delayed publication of financial statements, agreement on provision of additional liquidity, planned capital increase
DGAP-Adhoc: CO.DON AG: Delayed publication of financial statements, agreement on provision of additional liquidity, planned capital increase
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![DGAP-News: Epigenomics AG: Epi proColon in die 2020er Richtlinien zur Darmkrebs-Früherkennung des National Comprehensive Cancer Network aufgenommen](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
DGAP-News: Epigenomics AG: Epi proColon in die 2020er Richtlinien zur Darmkrebs-Früherkennung des National Comprehensive Cancer Network aufgenommen
DGAP-News: Epigenomics AG: Epi proColon in die 2020er Richtlinien zur Darmkrebs-Früherkennung des National Comprehensive Cancer Network aufgenommen
![DGAP-News: Epigenomics AG: Epi proColon included in 2020 National Comprehensive Cancer Network Colorectal Cancer Screening Guidelines](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
DGAP-News: Epigenomics AG: Epi proColon included in 2020 National Comprehensive Cancer Network Colorectal Cancer Screening Guidelines
DGAP-News: Epigenomics AG: Epi proColon included in 2020 National Comprehensive Cancer Network Colorectal Cancer Screening Guidelines
![DGAP-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-Adhoc: BB Biotech AG publishes its interim report
![DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
![DGAP-News: BB BIOTECH AG: Resilient biotech sector despite widespread market turmoil](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
DGAP-News: BB BIOTECH AG: Resilient biotech sector despite widespread market turmoil
DGAP-News: BB BIOTECH AG: Resilient biotech sector despite widespread market turmoil
![DGAP-News: BB BIOTECH AG: Resilienter Biotechsektor trotz breiter Marktturbulenzen](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: BB BIOTECH AG: Resilienter Biotechsektor trotz breiter Marktturbulenzen
DGAP-News: BB BIOTECH AG: Resilienter Biotechsektor trotz breiter Marktturbulenzen
![DGAP-Adhoc: MOLOGEN AG: Revocation of admission to Prime Standard](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
DGAP-Adhoc: MOLOGEN AG: Revocation of admission to Prime Standard
DGAP-Adhoc: MOLOGEN AG: Revocation of admission to Prime Standard
![DGAP-Adhoc: MOLOGEN AG: Widerruf der Zulassung zum Prime Standard](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
DGAP-Adhoc: MOLOGEN AG: Widerruf der Zulassung zum Prime Standard
DGAP-Adhoc: MOLOGEN AG: Widerruf der Zulassung zum Prime Standard
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten drei Monate 2020](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten drei Monate 2020
DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten drei Monate 2020
![DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2020](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2020
DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2020
![Pharnext Reports Financial Results for Year-End 2019](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Pharnext Reports Financial Results for Year-End 2019
Pharnext Reports Financial Results for Year-End 2019
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
![Pharnext and the University Hospital Institute Méditerranée Infection Announce a Joint Effort to Evaluate Repurposed Drugs for Potential Use Against the COVID-19 Virus](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Pharnext and the University Hospital Institute Méditerranée Infection Announce a Joint Effort to Evaluate Repurposed Drugs for Potential Use Against the COVID-19 Virus
Pharnext and the University Hospital Institute Méditerranée Infection Announce a Joint Effort to Evaluate Repurposed Drugs for Potential Use Against the COVID-19 Virus
![DGAP-News: EVOTEC SICHERT SICH GLOBALE RECHTE AN BETAZELL-ERSATZTHERAPIE: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-News: EVOTEC SICHERT SICH GLOBALE RECHTE AN BETAZELL-ERSATZTHERAPIE
DGAP-News: EVOTEC SICHERT SICH GLOBALE RECHTE AN BETAZELL-ERSATZTHERAPIE
![DGAP-News: EVOTEC REGAINS GLOBAL RIGHTS TO BETA CELL REPLACEMENT THERAPY: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-News: EVOTEC REGAINS GLOBAL RIGHTS TO BETA CELL REPLACEMENT THERAPY
DGAP-News: EVOTEC REGAINS GLOBAL RIGHTS TO BETA CELL REPLACEMENT THERAPY
DGAP-News: MorphoSys ernennt Dr. Roland Wandeler zum Chief Commercial Officer
DGAP-News: MorphoSys ernennt Dr. Roland Wandeler zum Chief Commercial Officer
DGAP-News: MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer
DGAP-News: MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer
![DGAP-Adhoc: HAEMATO AG: Gewinnverwendungsvorschlaghttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWlE9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--53b91026ff232fa7aa2f7da83a280c15c28ca459/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/haematoLogo.png?locale=us)
DGAP-Adhoc: HAEMATO AG: Gewinnverwendungsvorschlag
DGAP-Adhoc: HAEMATO AG: Gewinnverwendungsvorschlag